Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study.
Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study.
复制标题
DOI：
10.1186/1477-7819-11-298
复制
发表时间：
2013-11-22
影响因子：
3.2
通讯作者：
Brimo F
中科院分区：
文献类型：
--
作者：
Abourbih S;Sircar K;Tanguay S;Kassouf W;Aprikian A;Mansure J;Brimo F
ALDH1 已被证明是一种癌症干细胞标志物，其表达与许多恶性肿瘤的预后相关。我们的目的是评估原发性和转移性 RCC 标本队列中 ALDH1 的表达，并将表达与肿瘤分期和分级等病理结果以及无进展生存期等临床结果相关联。从 1985 年至 2006 年采集的 244 个 RCC 标本构建了三个组织微阵列。使用 ALDH1 单克隆抗体对样品进行染色，并根据染色程度对表达进行定量。膜和细胞质染色分开考虑。回顾性图表审查可以与临床结果相关联。 ALDH1 表达根据肿瘤分期 (P = 0.6274) 或级别 (P = 0.1666) 没有显着变化。与其他亚型相比，ALDH1 在透明细胞 RCC 中显示出显着更多的膜表达 (P < 0.0001)，以及与转移灶相比，在原发灶中 (P = 0.0216)。在无进展生存期方面，ALDH1 表达水平没有发现显着差异。在透明细胞肿瘤的亚组分析中，ALDH1膜表达在较高阶段的肿瘤中降低（P = 0.0233）。 ALDH1 可能有助于将 RCC 肿瘤表征为透明细胞亚型。然而，与其他恶性肿瘤不同，ALDH1 可能无法用于预测肾癌。在高阶段和转移环境中 ALDH1 表达降低的临床意义仍有待进一步研究确定。
ALDH1 has been shown to be a cancer stem cell marker, and its expression correlates with prognosis in a number of malignancies. We aimed to evaluate the expression of ALDH1 in a cohort of primary and metastatic RCC specimens, and to correlate expression with pathological outcomes such as tumor stage and grade, and clinical outcomes such as progression free survival. Three tissue microarrays were constructed from 244 RCC specimens, taken from 1985 to 2006. Samples were stained using an ALDH1 monoclonal antibody and expression was quantified by degree of staining. Membrane and cytoplasm staining were considered separately. A retrospective chart review enabled correlation with clinical outcomes. ALDH1 expression did not vary significantly based on tumor stage (P = 0.6274) or grade (P = 0.1666). ALDH1 showed significantly more membranous expression in clear cell RCC versus other subtypes (P < 0.0001), as well as in the primary setting compared to metastases (P = 0.0216). In terms of progression free survival, no significant differences were seen based on ALDH1 expression levels. In a subanalysis of clear cell tumors, ALDH1 membranous expression was decreased in tumors of higher stage (P = 0.0233). ALDH1 may be useful in characterizing RCC tumors as clear cell subtype. However, unlike in other malignancies, ALDH1 may not be useful in prognosticating renal cancers. The clinical significance of decreased ALDH1 expression in the high stage and metastatic setting remains to be determined in further investigations.